Precision BioSciences, Inc.
DTIL
Rank in Stocks
#15366
Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the... Precision BioSciences, Inc. is a clinical-stage biotechnology firm based in the United States, specializing in the creation of both in vivo gene editing solutions and ex vivo allogeneic CAR T-cell therapies. At its core is ARCUS, a proprietary genome editing platform designed to address and potentially cure genetic diseases. The company's portfolio also encompasses Ex vivo Allogeneic CAR T Immunotherapy, an innovative approach where specific immune cells, known as T-cells, are genetically modified outside the body to precisely identify and eliminate cancer cells. Among its prominent therapeutic candidates are: PBCAR0191, currently undergoing Phase 1/2a clinical trials for adult patients battling relapsed/refractory (R/R) non-Hodgkin lymphoma or R/R B-cell precursor acute lymphoblastic leukemia (B-ALL). PBCAR19B, an anti-CD19 CAR T candidate leveraging a "stealth cell" platform through a single-step gene edit, engineered to reduce the likelihood of chromosomal abnormalities. PBCAR269A, an investigational allogeneic CAR T immunotherapy formulated to target BCMA, intended for the treatment of R/R multiple myeloma. Precision BioSciences has strategically formed several collaborative alliances. These include an agreement with Les Laboratoires Servier for the development and commercialization of allogeneic chimeric antigen receptor T-cell therapies, aimed at various antigen targets, including hematological cancers beyond CD19, and solid tumors. The company is also partnering with Tiziana Life Sciences to assess foralumab, a fully human anti-CD3 monoclonal antibody, for its utility as a lymphodepleting agent in potential cancer treatments. Furthermore, a collaboration with iECURE, Inc. focuses on advancing ARCUS-based gene editing therapies. Established in 2006, Precision BioSciences, Inc. maintains its corporate headquarters in Durham, North Carolina.
Share Price
$9.68
Last synced: 2026-11-09
Market Cap
$267.18M
Change (1 day)
-8.68%
Change (1 year)
61.33%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Precision BioSciences, Inc. (DTIL)
Category
Healthcare
Operating Margin for Precision BioSciences, Inc. (DTIL)
Operating Margin as of November 2026 TTM: -80.78%
According to Precision BioSciences, Inc.'s latest financial reports, its current operating margin (TTM) is -80.78%. At the end of 2025 the company had an operating margin of -152.19%.
Operating Margin history for Precision BioSciences, Inc. from 2016 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | -80.78% | -46.92% |
| 2025 | -152.19% | 299.66% |
| 2024 | -38.08% | -57.58% |
| 2023 | -89.76% | -63.84% |
| 2022 | -248.26% | 628.46% |
| 2021 | -34.08% | -92.46% |
| 2020 | -452.25% | 15.33% |
| 2019 | -392.14% | -10.93% |
| 2018 | -440.25% | 29.91% |
| 2017 | -338.90% | 169.31% |
| 2016 | -125.84% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -100.48% |
US
|
|
| -149.01% | -98.16% |
US
|
|
| 25.57% | -100.32% |
AU
|
|
| 31.23% | -100.39% |
BE
|
|
| 29.35% | -100.36% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Precision BioSciences, Inc.'s operating margin
What is Precision BioSciences, Inc.'s operating margin?
Precision BioSciences, Inc.'s operating margin is -80.78%, as of Nov 2026.
What was Precision BioSciences, Inc.'s operating margin in 2025?
In 2025, Precision BioSciences, Inc.'s operating margin was -152.19%, compared with -38.08% in 2024.
How has Precision BioSciences, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Precision BioSciences, Inc.'s operating margin was highest in 2021 (-34.08%) and lowest in 2020 (-452.25%).
How does Precision BioSciences, Inc.'s operating margin compare with similar companies?
Precision BioSciences, Inc.'s operating margin (-80.78%) is higher than that of 1 of the 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.